The Latest Breaking News from FDA

There is a "warning of potentially serious or even deadly consequences from consuming the product"

The CISA and FDA have released security warnings about the Contec CMS8000, which is used for patient monitoring.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Three products from Cal Yee Farm’s recall last month are now a ‘Class 1’ level

As I’ve grown older and experienced the vagaries of my ageing memory, I’ve often reflected on the possibility of a miracle cure that would rejuvenate it. As if in answer to my wishful thinking, not one but several reports recently appeared simultaneously in the scientific news, highlighting a trending solution…

The new drug will be many times more expensive than a standard opioid option

Over 35 years after the first study linking Red 3 to thyroid cancer in rats was published, the US is beginning to wean it out of foods and drugs.

The industry ties and policy backgrounds of these officials and cabinet nominees are varied – and often contradictory

Suzetrigine, a new non-opioid pain relief drug sold under the brand name Journavx marks the first new class of pain reliever to receive FDA approval in over two decades.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids